Ligand Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Cantor Fitzgerald Reiterate Hold Following Ligand Pharma's (LGND) Strong Q1
May 13, 2015 7:23 AM EDTCantor Fitzgerald reiterate a Hold rating on Ligand Pharma (NASDAQ: LGND), and raise the price target to $86.00 (from $82.00), following a strong 1Q. LGND reported revenues of $14.6M, and an adjusted non-GAAP EPS of $0.33. Coming out ahead of FactSet consensus of $13.5M revenue and $0.27 EPS.... More
Ligand Pharma (LGND) PT Lifted to $127 at Roth Capital Following Q1 and as Pipeline Expands
May 11, 2015 11:34 AM EDTRoth Capital analyst Joseph Pantginis reiterated a Buy rating and boosted his price target on Ligand Pharma (NASDAQ: LGND) to $127.00 (from $116.00) following Q1 results.
LGND reported non-GAAP EPS of $0.33 vs. consensus of $0.27. LGND reported total revenues of $14.602 million vs. our estimate of $13.48 million and consensus... More
Ligand Pharma (LGND) Tops Q1 EPS by 6c
May 11, 2015 8:31 AM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.33, $0.06 better than the analyst estimate of $0.27. Revenue for the quarter came in at $14.6 million versus the consensus estimate of $13.5 million.
Ligand Pharma sees FY2015 EPS of $2.14-$2.18, versus the consensus of $2.13. Ligand Pharma sees FY2015... More
